Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank

2019 Younossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016/j.jhep.2019.06.021 Tavaglione, 2020, Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum, Endocrinol Diabetes Metab, 3, 10.1002/edm2.179 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Younossi, 2019, Non-alcoholic fatty liver disease – a global public health perspective, J Hepatol, 70, 531, 10.1016/j.jhep.2018.10.033 Blachier, 2013, The burden of liver disease in Europe: a review of available epidemiological data, J Hepatol, 58, 593, 10.1016/j.jhep.2012.12.005 Tsochatzis, 2014, Liver cirrhosis, Lancet, 383, 1749, 10.1016/S0140-6736(14)60121-5 Forner, 2012, Hepatocellular carcinoma, Lancet, 379, 1245, 10.1016/S0140-6736(11)61347-0 Eslam, 2018, Genetics and epigenetics of NAFLD and NASH: clinical impact, J Hepatol, 68, 268, 10.1016/j.jhep.2017.09.003 Romeo, 2020, Leveraging human genetics to identify potential new treatments for fatty liver disease, Cell Metab, 31, 35, 10.1016/j.cmet.2019.12.002 Björkström, 2019, Risk factors for severe liver disease in patients with type 2 diabetes, Clin Gastroenterol Hepatol, 17, 2769, 10.1016/j.cgh.2019.04.038 Sudlow, 2015, UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age, PLoS Med, 12, 10.1371/journal.pmed.1001779 Elliott, 2008, The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine, Int J Epidemiol, 37, 234, 10.1093/ije/dym276 Townsend, 1988 2016, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 64, 1388, 10.1016/j.jhep.2015.11.004 Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006 2020, Standards of medical care in diabetes, Diabetes Care, 43, S135, 10.2337/dc20-S011 Bycroft, 2018, The UK Biobank resource with deep phenotyping and genomic data, Nature, 562, 203, 10.1038/s41586-018-0579-z Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 40, 1461, 10.1038/ng.257 Kozlitina, 2014, Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 46, 352, 10.1038/ng.2901 Mancina, 2016, The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent, Gastroenterology, 150, 1219, 10.1053/j.gastro.2016.01.032 Valenti, 2012, Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms, Hepatology, 55, 661, 10.1002/hep.25617 Abul-Husn, 2018, A protein-truncating HSD17B13 variant and protection from chronic liver disease, N Engl J Med, 378, 1096, 10.1056/NEJMoa1712191 Alberti, 2006, Metabolic syndrome – a new world-wide definition. A consensus statement from the International Diabetes Federation, Diabet Med, 23, 469, 10.1111/j.1464-5491.2006.01858.x Prati, 2002, Updated definitions of healthy ranges for serum alanine aminotransferase levels, Ann Intern Med, 137, 1, 10.7326/0003-4819-137-1-200207020-00006 Dongiovanni, 2015, Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease, Hepatology, 61, 506, 10.1002/hep.27490 Speliotes, 2011, Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits, PLoS Genet, 7, 10.1371/journal.pgen.1001324 Botros, 2013, The de ritis ratio: the test of time, Clin Biochem Rev, 34, 117 Verma, 2013, Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD), Liver Int, 33, 1398, 10.1111/liv.12226 Doycheva, 2016, Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE, Aliment Pharmacol Ther, 43, 83, 10.1111/apt.13405 Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265 Lomonaco, 2016, Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes, Diabetes Care, 39, 632, 10.2337/dc15-1876 Roerecke, 2019, Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis, Am J Gastroenterol, 114, 1574, 10.14309/ajg.0000000000000340 Kautzky-Willer, 2016, Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus, Endocr Rev, 37, 278, 10.1210/er.2015-1137 Penno, 2011, Clinical significance of nonalbuminuric renal impairment in type 2 diabetes, J Hypertens, 29, 1802, 10.1097/HJH.0b013e3283495cd6 Buch, 2015, A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis, Nat Genet, 47, 1443, 10.1038/ng.3417 Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405 Elkrief, 2016, Diabetes mellitus in patients with cirrhosis: clinical implications and management, Liver Int, 36, 936, 10.1111/liv.13115 Orsi, 2017, Hepatogenous diabetes: is it time to separate it from type 2 diabetes?, Liver Int, 37, 950, 10.1111/liv.13337 Bhattacharjee, 2019, Utility of HbA1c assessment in people with diabetes awaiting liver transplantation, Diabet Med, 36, 1444, 10.1111/dme.13870 Pugliese, 2014, Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study, Nutr Metab Cardiovasc Dis, 24, 815, 10.1016/j.numecd.2014.02.013